Relapsing remitting multiple sclerosis Trials in Berlin, Germany
Conditions / Relapsing remitting multiple sclerosis / Berlin, Germany
Relapsing remitting multiple sclerosis has been the subject of sustained clinical investigation across multiple research sites.
27 total trials for this combination
Showing top 10 of 27 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT00451451 | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT00879658 | Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis | COMPLETED | PHASE2 |
| NCT02255656 | Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 | COMPLETED | PHASE4 |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | COMPLETED | PHASE3 |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo | COMPLETED | PHASE3 |
| NCT00493298 | Tysabri Observational Program | COMPLETED | — |
| NCT00297232 | Natalizumab (Tysabri) Re-Initiation of Dosing | TERMINATED | PHASE3 |
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT01436643 | Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression | TERMINATED | PHASE4 |